Phibro Animal Health Corporation beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +9.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q3 FY26 | $0.72 | $0.76 | +5.6% | Beat | |
| Q2 FY26 | $0.69 | $0.87 | +26.1% | Beat | Q2 FY26 call |
| Q1 FY26 | $0.59 | $0.73 | +23.7% | Beat | |
| Q4 FY25 | $0.52 | $0.57 | +9.6% | Beat | Q4 FY25 call |
| Q3 FY25 | $0.52 | $0.63 | +21.1% | Beat | |
| Q2 FY25 | $0.42 | $0.54 | +28.6% | Beat | |
| Q1 FY25 | $0.23 | $0.35 | +52.2% | Beat | |
| Q4 FY24 | $0.34 | $0.41 | +20.6% | Beat | |
| Q3 FY24 | $0.29 | $0.31 | +6.9% | Beat | |
| Q2 FY24 | $0.27 | $0.33 | +22.2% | Beat | |
| Q1 FY24 | $0.21 | $0.14 | -33.3% | Miss | |
| Q4 FY23 | $0.40 | $0.38 | -5.0% | Miss |
Back to PAHC overview · PAHC holders · PAHC KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.